<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383552</url>
  </required_header>
  <id_info>
    <org_study_id>P04073</org_study_id>
    <secondary_id>Doc ID: 3100873;</secondary_id>
    <secondary_id>EUDRACT No: 2006-001577-13;</secondary_id>
    <nct_id>NCT00383552</nct_id>
  </id_info>
  <brief_title>Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)</brief_title>
  <official_title>A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects With Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multi-center, double-blind, double-dummy, placebo-controlled,
      parallel-group study, evaluating the efficacy of mometasone furoate/formoterol fumarate
      (MF/F) metered dose inhaler (MDI) versus MF for 26 weeks. Prior to the 26-week double-blind
      Treatment Period, participants will receive open-label (OL) MF MDI 100 mcg twice daily (BID)
      for 2 to 3 weeks during the Run-in Period. Efficacy will be measured by the Area Under the
      Curve from 0 to 12 hours [AUC](0-12 hours) of the change from Baseline to the Week 12
      Endpoint in Forced Expiratory Volume in One Second (FEV1) and by the time-to-first severe
      asthma exacerbation across the 26-week treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The average of the two predose FEV1 measurements (30 minutes prior to dosing and 0 hour, immediately prior to dosing) at the Baseline Visit were subtracted from each of the serial measurements over the 12-hour period. The AUC was calculated based on these changes from Baseline evaluations. The comparison was for MF/F vs MF. Standard deviation was pooled.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Time-to-first Severe Asthma Exacerbation Over the 26-week Treatment Period</measure>
    <time_frame>Across the 26 week treatment period</time_frame>
    <description>Severe asthma exacerbation refers to an occurrence of a decrease below 80% of Baseline in FEV1, a decrease below 70% of Baseline in PEF on 2 consecutive days or a clinical deterioration of asthma resulting in emergency treatment, hospitalization or treatment with asthma medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With at Least One Severe Asthma Exacerbation at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Severe asthma exacerbation refers to an occurrence of a decrease below 80% of Baseline in FEV1, a decrease below 70% of Baseline in PEF on 2 consecutive days and or a clinical deterioration of asthma resulting in emergency treatment, hospitalization or treatment with asthma medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 26 in the Asthma Control Questionnaire (ACQ) Total Score</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>ACQ consists of seven questions each scaled from 0 (best case) to 6 (worst case). The comparison was for MF/F vs placebo. Standard deviation was pooled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 26 in Asthma Quality of Life Questionnaire With Standarized Activities (AQLQ[S]) Total Score</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>AQLQ(S) consists of 32 questions each scaled from 1 (worst case) to 7 (best case). The comparison was for MF/F vs placebo. Standard deviation was pooled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Proportion of Nights Across the Treatment Period With Nocturnal Awakenings Due to Asthma Which Require Use of Short-acting Beta Agonists (SABA)</measure>
    <time_frame>Baseline to Endpoint</time_frame>
    <description>Baseline is the proportion of nights of the last week (Days -7 to 1) prior to first dose with nocturnal awakenings. Scale is measured as 0 to 1 with 0=no awakenings to 1=awakenings every night. The comparison was for MF/F vs placebo. Standard deviation was pooled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AM FEV1 Pre-dose Assessment, or Trough FEV1, at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Trough FEV1 is a measure of the end-of-dosing interval. The comparison was for MF/F vs F. Standard deviation was pooled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-12 Hour) of the Change From Baseline to Week 12 in FEV1 for Each Body Mass Index (BMI) Subgroup</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The average of the two predose FEV1 measurements (30 minutes prior to dosing and 0 hour, immediately prior to dosing) at the Baseline Visit were subtracted from each of the serial measurements over the 12-hour period. The AUC was calculated based on these changes from Baseline evaluations. BMI is a number calculated from a person's weight and height. The higher the number, the higher the amount of fat. The comparison was for MF/F vs placebo. Standard deviation was pooled.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">746</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>MF/F MDI 100/10 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MF MDI 100 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>F MDI 10 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID</intervention_name>
    <description>MF/F 100/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks</description>
    <arm_group_label>MF/F MDI 100/10 mcg BID</arm_group_label>
    <other_name>SCH 418131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate MDI (MF MDI)</intervention_name>
    <description>MF 100 mcg via metered dose inhaler twice daily for 26 weeks</description>
    <arm_group_label>MF MDI 100 mcg BID</arm_group_label>
    <other_name>SCH 32088</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Fumarate 10 mcg</intervention_name>
    <description>F via metered dose inhaler 10 mcg twice a day for 26 weeks</description>
    <arm_group_label>F MDI 10 mcg BID</arm_group_label>
    <other_name>Foradil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo metered dose inhaler twice a day for 26 weeks</description>
    <arm_group_label>Placebo BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;=12 years, either sex, any race, asthma diagnosis &gt;=12 months that is consistent with
             the following: Diagnosis based on clinical history &amp; examination, pulmonary function
             parameters &amp; response to beta-2-agonists, according to international guidelines.

          -  Been using low daily dose of inhaled corticosteroid (ICS) (either alone or in
             combination with long-acting beta agonist [LABA]) &gt;=12 weeks &amp; been on stable asthma
             regimen for &gt;=2 weeks prior to Screening. Low daily doses of ICS are:

        200-500 mcg beclomethasone chlorofluorocarbon (CFC),

        100-250 mcg beclomethasone hydrofluoroalkane (HFA),

        200-600 mcg budesonide dry powder inhaler (DPI),

        500-1000 mcg flunisolide,

        100-250 mcg fluticasone,

        200 mcg MF,

        400-1000 mcg triamcinolone acetonide,

        80 to 160 mcg ciclesonide.

        Note: Dose delivery by method/modality other than these must be equivalent.

          -  No harm in changing current asthma therapy to investigator, subject (legal
             representation, if applicable) must be willing to discontinue his/her ICS or ICS/LABA
             combination prior to initiating MF MDI run-in medication at Screening Visit, &amp;
             transferred to open-label treatment with MF MDI 100 mcg BID for 2-3 weeks prior to
             Baseline Visit.

          -  To document diagnosis of asthma &amp; assure responsiveness to bronchodilators before
             randomization 1 of these can be used at Screening Visit or thereafter, but prior to
             Baseline Visit:

        Demonstrate increase in absolute FEV1 &gt;=12% &amp; &gt;=200 mL within approximately 15 to 20
        minutes after administration of 4 inhalations of albuterol/salbutamol (total dose 360-400
        mcg) or nebulized short-acting beta agonist (SABA) (2.5 mg) if confirmed as standard office
        practice, OR

        Demonstrate peak expiratory flow (PEF) variability &gt;20% expressed as percentage of the mean
        highest &amp; lowest morning prebronchodilator (before taking albuterol/salbutamol) PEF over
        &gt;=1 week, OR

        Demonstrate diurnal variation in PEF of &gt;20% based on difference between prebronchodilator
        (before taking albuterol/salbutamol) morning value &amp; postbronchodilator value (after taking
        albuterol/salbutamol) from evening before, expressed as percentage of mean daily PEF value.

          -  At Screening Visit, FEV1 must be &gt;=60% &amp; &lt;=90% predicted.

          -  At Baseline Visit, FEV1 must be &gt;=60% &amp; &lt;=85% predicted when all restricted drugs have
             been withheld for appropriate intervals.

          -  Lab tests at Screening Visit must be normal or acceptable to investigator/sponsor and
             include serum pregnancy for females of child-bearing potential). Electrocardiogram
             (ECG) at Screening Visit, using centralized trans-telephonic technology must be
             acceptable to investigator. Chest x-ray performed at Screening Visit or within 12
             months prior to Screening Visit must be acceptable to investigator.

          -  Subject (legal representation, if applicable) must be willing to give written informed
             consent &amp; able to adhere to schedules.

          -  A non-pregnant woman of childbearing potential must use birth control. Includes:
             hormonal contraceptives including hormonal vaginal ring, hormonal implant or
             depot-injectable; Intrauterine device (IUD); medically prescribed topically-applied
             transdermal contraceptive patch; condom in combination with spermicide; monogamous
             relationship with male who had vasectomy. Started birth control method &gt;=3 months
             prior to Screening (exception condom), &amp; must agree to continue its use. Female of
             childbearing potential who is not currently sexually active must agree &amp; consent to
             using birth control, should she become active. Women who have been surgically
             sterilized or are &gt;=1 year postmenopausal are not considered to be of childbearing
             potential. Female must have negative serum pregnancy test at Screening.

        Exclusion Criteria:

          -  Increase/decrease in absolute FEV1 of &gt;20% at any time from Screening Visit up to &amp;
             including Baseline Visit. Pulmonary function tests (PFTs) will be performed in the
             morning.

          -  &gt;8 inhalations/day of SABA MDI or &gt;=2 nebulized treatments/day of 2.5 mg SABA on 2
             consecutive days from Screening Visit up to &amp; including Baseline Visit.

          -  Decrease in AM/PM PEF below Screening Period stability limit on 2 consecutive days
             prior to randomization.

          -  Asthma deterioration results in emergency treatment, hospitalization, or treatment
             with additional, excluded asthma medication (including oral or other systemic
             corticosteroids, but allowing SABA) as judged by investigator at any time from
             Screening Visit up to &amp; including Baseline Visit.

          -  Treated in emergency room (ER) (for severe asthma exacerbation requiring systemic
             glucocorticosteroid treatment) or admitted to hospital for management of airway
             obstruction within last 3 months.

          -  Ever required ventilator support for respiratory failure secondary to asthma.

          -  Upper/lower respiratory tract infection within previous 2 weeks prior to Screening &amp;
             Baseline Visits. Visits can be rescheduled 2 weeks after complete resolution.

          -  Smoker or ex-smoker &amp; has smoked within previous year or has cumulative smoking
             history &gt;10 pack-years.

          -  Significant abnormal vital sign.

          -  Evidence upon visual inspection of significant oropharyngeal candidiasis at Baseline
             or earlier with or without treatment. If there is evidence at Screening or
             Pre-Baseline Visit, may be treated as appropriate &amp; Baseline Visit can be scheduled
             upon resolution.

          -  History of significant renal, hepatic, cardiovascular, metabolic, neurologic,
             hematologic, ophthalmologic, respiratory, gastrointestinal, cerebrovascular, or other
             which, in judgment of investigator, could interfere with study or require treatment
             which might interfere with study. Examples include (but are not limited to)
             insulin-dependent diabetes, hypertension being treated with beta-blockers, active
             hepatitis, coronary artery disease, arrhythmia, significant QTc prolongation (ie QTcF
             or QTcB [Fridericia or Bazett corrections, respectively &gt;500 msecs), stroke, severe
             rheumatoid arthritis, chronic open-angle glaucoma or posterior subcapsular cataracts
             (including prior cataract surgery), acquired immune deficiency syndrome (AIDS), or
             conditions that may interfere with respiratory function such as chronic obstructive
             pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, cystic
             fibrosis. Others which are well-controlled &amp; stable (eg hypertension not requiring
             beta-blockers) will not prohibit participation if deemed appropriate by investigator.

          -  Allergic/intolerant of glucocorticoids, beta-2-agonists, or any inactive excipients in
             study drugs.

          -  Female who is breast-feeding, pregnant, or intends to become pregnant while in study.

          -  Illicit drug user.

          -  Human immunodeficiency virus (HIV) positive (testing not done).

          -  Unable to use oral MDI inhaler.

          -  Has been taking any restricted medications prior to Screening without meeting required
             washout.

          -  Cannot adhere to prohibited &amp; permitted concomitant medications.

          -  May not participate in same study at another site. Cannot participate in different
             study at any site, during same time.

          -  Must not be randomized into study more than once.

          -  No person directly associated with administration of study may participate.

          -  Previously participated in trial with MF/F.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>Ecuador</country>
    <country>Estonia</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Meltzer EO, Kuna P, Nolte H, Nayak AS, Laforce C; P04073 Study Investigators. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur Respir J. 2012 Feb;39(2):279-89. doi: 10.1183/09031936.00020310. Epub 2011 Aug 4.</citation>
    <PMID>21828036</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2006</study_first_submitted>
  <study_first_submitted_qc>September 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2006</study_first_posted>
  <results_first_submitted>July 15, 2010</results_first_submitted>
  <results_first_submitted_qc>September 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 25, 2011</results_first_posted>
  <disposition_first_submitted>April 14, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>October 16, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 20, 2009</disposition_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MF/F MDI 100/10 mcg BID</title>
          <description>Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)</description>
        </group>
        <group group_id="P2">
          <title>MF MDI 100 mcg BID</title>
          <description>Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)</description>
        </group>
        <group group_id="P3">
          <title>F MDI 10 mcg BID</title>
          <description>Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)</description>
        </group>
        <group group_id="P4">
          <title>Placebo BID</title>
          <description>Placebo twice daily (BID)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="188"/>
                <participants group_id="P3" count="188"/>
                <participants group_id="P4" count="188"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="147"/>
                <participants group_id="P3" count="127"/>
                <participants group_id="P4" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="72"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not wish to continue (unrelated)</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not wish to continue (related)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with the protocol</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet protocol eligibility</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MF/F MDI 100/10 mcg BID</title>
          <description>Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)</description>
        </group>
        <group group_id="B2">
          <title>MF MDI 100 mcg BID</title>
          <description>Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)</description>
        </group>
        <group group_id="B3">
          <title>F MDI 10 mcg BID</title>
          <description>Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)</description>
        </group>
        <group group_id="B4">
          <title>Placebo BID</title>
          <description>Placebo twice daily (BID)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="182"/>
            <count group_id="B2" value="188"/>
            <count group_id="B3" value="188"/>
            <count group_id="B4" value="188"/>
            <count group_id="B5" value="746"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.1" spread="16.9"/>
                    <measurement group_id="B2" value="39.4" spread="16.7"/>
                    <measurement group_id="B3" value="38.5" spread="15.6"/>
                    <measurement group_id="B4" value="38.1" spread="17.4"/>
                    <measurement group_id="B5" value="38.3" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="106"/>
                    <measurement group_id="B5" value="413"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)</title>
        <description>The average of the two predose FEV1 measurements (30 minutes prior to dosing and 0 hour, immediately prior to dosing) at the Baseline Visit were subtracted from each of the serial measurements over the 12-hour period. The AUC was calculated based on these changes from Baseline evaluations. The comparison was for MF/F vs MF. Standard deviation was pooled.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg BID</title>
            <description>Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)</title>
          <description>The average of the two predose FEV1 measurements (30 minutes prior to dosing and 0 hour, immediately prior to dosing) at the Baseline Visit were subtracted from each of the serial measurements over the 12-hour period. The AUC was calculated based on these changes from Baseline evaluations. The comparison was for MF/F vs MF. Standard deviation was pooled.</description>
          <population>Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).</population>
          <units>liters * hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94" spread="3.29"/>
                    <measurement group_id="O2" value="1.85" spread="3.29"/>
                    <measurement group_id="O3" value="4.09" spread="3.29"/>
                    <measurement group_id="O4" value="1.64" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="3.71"/>
                    <measurement group_id="O2" value="2.53" spread="3.71"/>
                    <measurement group_id="O3" value="3.83" spread="3.71"/>
                    <measurement group_id="O4" value="1.11" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 26 in the Asthma Control Questionnaire (ACQ) Total Score</title>
        <description>ACQ consists of seven questions each scaled from 0 (best case) to 6 (worst case). The comparison was for MF/F vs placebo. Standard deviation was pooled.</description>
        <time_frame>Baseline to Week 26</time_frame>
        <population>Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg BID</title>
            <description>Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 26 in the Asthma Control Questionnaire (ACQ) Total Score</title>
          <description>ACQ consists of seven questions each scaled from 0 (best case) to 6 (worst case). The comparison was for MF/F vs placebo. Standard deviation was pooled.</description>
          <population>Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="129"/>
                <count group_id="O4" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="0.71"/>
                    <measurement group_id="O2" value="1.29" spread="0.60"/>
                    <measurement group_id="O3" value="1.38" spread="0.76"/>
                    <measurement group_id="O4" value="1.23" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.65"/>
                    <measurement group_id="O2" value="-0.32" spread="0.65"/>
                    <measurement group_id="O3" value="-0.12" spread="0.65"/>
                    <measurement group_id="O4" value="-0.11" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Time-to-first Severe Asthma Exacerbation Over the 26-week Treatment Period</title>
        <description>Severe asthma exacerbation refers to an occurrence of a decrease below 80% of Baseline in FEV1, a decrease below 70% of Baseline in PEF on 2 consecutive days or a clinical deterioration of asthma resulting in emergency treatment, hospitalization or treatment with asthma medication.</description>
        <time_frame>Across the 26 week treatment period</time_frame>
        <population>Medians for time-to-event outcomes are estimated for those who had events.</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 Mcg BID</title>
            <description>Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 Mcg BID</title>
            <description>Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID).</description>
          </group>
          <group group_id="O3">
            <title>F MDI 10 Mcg BID</title>
            <description>Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID).</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time-to-first Severe Asthma Exacerbation Over the 26-week Treatment Period</title>
          <description>Severe asthma exacerbation refers to an occurrence of a decrease below 80% of Baseline in FEV1, a decrease below 70% of Baseline in PEF on 2 consecutive days or a clinical deterioration of asthma resulting in emergency treatment, hospitalization or treatment with asthma medication.</description>
          <population>Medians for time-to-event outcomes are estimated for those who had events.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" spread="101" lower_limit="11" upper_limit="101"/>
                    <measurement group_id="O2" value="54" spread="98" lower_limit="12" upper_limit="98"/>
                    <measurement group_id="O3" value="51.5" spread="125.5" lower_limit="16.5" upper_limit="125.5"/>
                    <measurement group_id="O4" value="27.5" spread="87" lower_limit="8" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 26 in Asthma Quality of Life Questionnaire With Standarized Activities (AQLQ[S]) Total Score</title>
        <description>AQLQ(S) consists of 32 questions each scaled from 1 (worst case) to 7 (best case). The comparison was for MF/F vs placebo. Standard deviation was pooled.</description>
        <time_frame>Baseline to Week 26</time_frame>
        <population>Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg BID</title>
            <description>Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 26 in Asthma Quality of Life Questionnaire With Standarized Activities (AQLQ[S]) Total Score</title>
          <description>AQLQ(S) consists of 32 questions each scaled from 1 (worst case) to 7 (best case). The comparison was for MF/F vs placebo. Standard deviation was pooled.</description>
          <population>Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="129"/>
                <count group_id="O4" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.60" spread="0.93"/>
                    <measurement group_id="O2" value="5.65" spread="1.00"/>
                    <measurement group_id="O3" value="5.60" spread="0.98"/>
                    <measurement group_id="O4" value="5.76" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.73"/>
                    <measurement group_id="O2" value="0.39" spread="0.73"/>
                    <measurement group_id="O3" value="0.15" spread="0.73"/>
                    <measurement group_id="O4" value="0.06" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Proportion of Nights Across the Treatment Period With Nocturnal Awakenings Due to Asthma Which Require Use of Short-acting Beta Agonists (SABA)</title>
        <description>Baseline is the proportion of nights of the last week (Days -7 to 1) prior to first dose with nocturnal awakenings. Scale is measured as 0 to 1 with 0=no awakenings to 1=awakenings every night. The comparison was for MF/F vs placebo. Standard deviation was pooled.</description>
        <time_frame>Baseline to Endpoint</time_frame>
        <population>Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg BID</title>
            <description>Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Proportion of Nights Across the Treatment Period With Nocturnal Awakenings Due to Asthma Which Require Use of Short-acting Beta Agonists (SABA)</title>
          <description>Baseline is the proportion of nights of the last week (Days -7 to 1) prior to first dose with nocturnal awakenings. Scale is measured as 0 to 1 with 0=no awakenings to 1=awakenings every night. The comparison was for MF/F vs placebo. Standard deviation was pooled.</description>
          <population>Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).</population>
          <units>Proportion of Nights</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="185"/>
                <count group_id="O4" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.12"/>
                    <measurement group_id="O2" value="0.12" spread="0.12"/>
                    <measurement group_id="O3" value="0.15" spread="0.15"/>
                    <measurement group_id="O4" value="0.13" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.16"/>
                    <measurement group_id="O2" value="-0.03" spread="0.16"/>
                    <measurement group_id="O3" value="-0.03" spread="0.16"/>
                    <measurement group_id="O4" value="0.02" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AM FEV1 Pre-dose Assessment, or Trough FEV1, at Week 12</title>
        <description>Trough FEV1 is a measure of the end-of-dosing interval. The comparison was for MF/F vs F. Standard deviation was pooled.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg BID</title>
            <description>Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in AM FEV1 Pre-dose Assessment, or Trough FEV1, at Week 12</title>
          <description>Trough FEV1 is a measure of the end-of-dosing interval. The comparison was for MF/F vs F. Standard deviation was pooled.</description>
          <population>Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="2.56"/>
                    <measurement group_id="O2" value="2.41" spread="2.46"/>
                    <measurement group_id="O3" value="2.47" spread="2.52"/>
                    <measurement group_id="O4" value="2.46" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.21"/>
                    <measurement group_id="O2" value="0.16" spread="0.21"/>
                    <measurement group_id="O3" value="0.11" spread="0.21"/>
                    <measurement group_id="O4" value="0.04" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.073</p_value>
            <method>Longitudinal Model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-12 Hour) of the Change From Baseline to Week 12 in FEV1 for Each Body Mass Index (BMI) Subgroup</title>
        <description>The average of the two predose FEV1 measurements (30 minutes prior to dosing and 0 hour, immediately prior to dosing) at the Baseline Visit were subtracted from each of the serial measurements over the 12-hour period. The AUC was calculated based on these changes from Baseline evaluations. BMI is a number calculated from a person's weight and height. The higher the number, the higher the amount of fat. The comparison was for MF/F vs placebo. Standard deviation was pooled.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg BID</title>
            <description>Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12 Hour) of the Change From Baseline to Week 12 in FEV1 for Each Body Mass Index (BMI) Subgroup</title>
          <description>The average of the two predose FEV1 measurements (30 minutes prior to dosing and 0 hour, immediately prior to dosing) at the Baseline Visit were subtracted from each of the serial measurements over the 12-hour period. The AUC was calculated based on these changes from Baseline evaluations. BMI is a number calculated from a person's weight and height. The higher the number, the higher the amount of fat. The comparison was for MF/F vs placebo. Standard deviation was pooled.</description>
          <population>Efficacy analyses were based on randomized participants with Baseline and any post-baseline data (intent-to-treat principle).</population>
          <units>liters * hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Less than 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.24" spread="4.42"/>
                    <measurement group_id="O2" value="3.19" spread="4.42"/>
                    <measurement group_id="O3" value="4.34" spread="4.42"/>
                    <measurement group_id="O4" value="2.22" spread="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 to less than 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="4.14"/>
                    <measurement group_id="O2" value="3.23" spread="4.14"/>
                    <measurement group_id="O3" value="4.26" spread="4.14"/>
                    <measurement group_id="O4" value="1.22" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 or more</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" spread="3.68"/>
                    <measurement group_id="O2" value="1.69" spread="3.68"/>
                    <measurement group_id="O3" value="3.13" spread="3.68"/>
                    <measurement group_id="O4" value="-0.73" spread="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>BMI 25 to &lt;30</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>BMI less than 25 and for BMI 30 or more</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With at Least One Severe Asthma Exacerbation at Week 26</title>
        <description>Severe asthma exacerbation refers to an occurrence of a decrease below 80% of Baseline in FEV1, a decrease below 70% of Baseline in PEF on 2 consecutive days and or a clinical deterioration of asthma resulting in emergency treatment, hospitalization or treatment with asthma medication.</description>
        <time_frame>Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg BID</title>
            <description>Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) 100/10 mcg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>Mometasone Furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol Fumarate (F) metered dose inhaler (MDI) 10 mcg twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Severe Asthma Exacerbation at Week 26</title>
          <description>Severe asthma exacerbation refers to an occurrence of a decrease below 80% of Baseline in FEV1, a decrease below 70% of Baseline in PEF on 2 consecutive days and or a clinical deterioration of asthma resulting in emergency treatment, hospitalization or treatment with asthma medication.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All participants treated with OL MF MDI and/or double-blind study medication are included in the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>OL MF MDI 100 MCG BID</title>
          <description>Open-label (OL) mometasone furoate (MF) metered dose inhaler (MDI) 100 mcg twice daily (BID). Participants received 2- to 3-weeks (approximately) of open-label run-in with MF MDI 100 mcg BID prior to the 26-week double-blind Treatment Period.</description>
        </group>
        <group group_id="E2">
          <title>MF/F MDI 100/10 MCG BID</title>
        </group>
        <group group_id="E3">
          <title>MF MDI 100 MCG BID</title>
        </group>
        <group group_id="E4">
          <title>F MDI 10 MCG BID</title>
        </group>
        <group group_id="E5">
          <title>PLACEBO</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="882"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="188"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY VALVE STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>DEAFNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>VIRAL PERICARDITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>DYSFUNCTIONAL UTERINE BLEEDING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>FALLOPIAN TUBE CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="882"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="882"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="882"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="882"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="182"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="188"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="188"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="882"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="182"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="188"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="188"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="882"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="182"/>
                <counts group_id="E3" events="19" subjects_affected="17" subjects_at_risk="188"/>
                <counts group_id="E4" events="26" subjects_affected="20" subjects_at_risk="188"/>
                <counts group_id="E5" events="17" subjects_affected="12" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="882"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="182"/>
                <counts group_id="E3" events="18" subjects_affected="11" subjects_at_risk="188"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="188"/>
                <counts group_id="E5" events="10" subjects_affected="7" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees not to publish/present any interim results without prior
sponsor written consent. The investigator agrees to provide to the sponsor, 45 days prior to submission, review copies for publication that report any study results. The sponsor has the right to review and comment. If the parties disagree, investigator agrees to meet with the sponsor, prior to submission for publication, to discuss and resolve any such issues/disagreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

